On May 19, 2025 Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), reported that members of the management team will participate in two upcoming investor conferences (Press release, Molecular Partners, MAY 19, 2025, View Source [SID1234653218]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ:
Fireside Chat on Tuesday May 20, 2025 beginning at 3:30pm ET
TD Cowen’s 6th Annual Oncology Innovation Summit: Insights for ASCO (Free ASCO Whitepaper) & EHA (Free EHA Whitepaper):
Fireside chat on Wednesday, May 28, 2025 beginning at 10:00am ET
Both events will be webcast and available on the Molecular Partners website, under the investors tab.